Skip to content
Search

Latest Stories

Dementia: Pharmacists to explore how to enhance patient care in upcoming webinar

Dementia: Pharmacists to explore how to enhance patient care in upcoming webinar

Experts will address the growing challenges in dementia treatment and explore ways to optimise pathways between primary and secondary care

Dementia and Alzheimer's disease remained the leading cause of death in England and Wales in 2023, maintaining the pre-pandemic trend, according to the latest data from the Office for National Statistics (ONS).

The figures reveal that there were 66,876 deaths with an underlying cause of dementia and Alzheimer's disease, accounting for 11.6% of all deaths registered that year.


In response to this growing health concern, Luye Pharma is hosting a free special educational webinar on 6 November 2024 (timing: 18:30 - 20:00) for healthcare professionals.

Titled "Treating Dementia in 2024: Optimising Pathways Between Primary and Secondary Care," the online session will focus on addressing the ever-increasing challenges in dementia treatment and how to optimise pathways between primary and secondary care.

The webinar will feature expert speakers from the field of dementia care, including Dr. Jill Rasmussen, Primary Care Specialist in dementia, mental health, and intellectual disabilities; Delia Bashara, Consultant Pharmacist for the Mental Health of Older Adults and Dementia at South London and Maudsley NHS Foundation Trust; and Khaleel Loonat, Senior Clinical Pharmacist and Advanced Clinical Practitioner.

Dr. Rasmussen will cover "Issues and Challenges in Managing People with Dementia: Focus on Pathways and Treatments," Delia Bashara will speak on "Dementia Pathways in Secondary Care," and Khaleel Loonat will discuss "Dementia Care: The Use of Transdermal Patches in Primary Care."

The session aims to provide valuable guidance on managing dementia within the current healthcare environment.

Luye Pharma, specializing in diseases of the central nervous system (CNS), has developed Zeyzelf, a twice-weekly transdermal rivastigmine patch for treating Alzheimer’s dementia.

This webinar presents an opportunity for healthcare professionals to learn more about managing and treating dementia.

You can register for the event at the following link: https://hcpconnect-uniphar.com/treating-dementia-in-2024/

Nearly 1 million people in the UK are estimated to have dementia. In hospitals, one in four beds is occupied by individuals over the age of 65 who are living with dementia. Projections suggest that by 2040, up to 1.7 million people could be living with the condition in England and Wales.

 

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less